Results 141 to 150 of about 967,275 (342)

Development and evaluation of DNA vaccines in chickens against a wild bird H6N2 avian influenza virus from Western Australia

, 2010
Genetic immunization, also known as DNA or polynucleotide immunisation, is well documented to induce broad-based immunity in various animal models of infectious and non-infectious diseases.
Shan, Songhua
core  

Multivalent COBRA Hemagglutinin and Neuraminidase Influenza Vaccines Adjuvanted with TLR9 Agonist CpG 1018

Background/Objectives: There is a need for effective seasonal influenza virus vaccines that provide broad and long-lasting protection against influenza virus infections.
Ted M. Ross, Pedro L. Sanchez, Amanda Lynch   +2 more
core   +1 more source

AS03- and MF59-Adjuvanted Influenza Vaccines in Children

Frontiers in Immunology, 2017
Influenza is a major cause of respiratory disease leading to hospitalization in young children. However, seasonal trivalent influenza vaccines (TIVs) have been shown to be ineffective and poorly immunogenic in this population.
A. Wilkins, Dmitri Kazmin, G. Napolitani, E. Clutterbuck, B. Pulendran, C. Siegrist, A. Pollard   +6 more
semanticscholar   +1 more source

Heat Stress and Gut Microbiome Dynamics in Poultry: Interplay, Consequences, and Mitigation Strategies

Animal Research and One Health, EarlyView.
Heat stress disrupts gut microbial balance in poultry, impairing nutrient absorption and immunity. This review outlines the interplay between thermal stress and microbiome dynamics and discusses integrative mitigation strategies, probiotics, phytogenics, cooling systems, and genetic adaptation to enhance poultry resilience.
O. E. Oke, A. I. Oni, O. A. Akosile, K. M. Oliyide, C. A. Ishola, M. O. Logunleko, O. A. Jimoh, C. P. Njoku, L. O. Fasasi, V. A. Uyanga   +9 more
wiley   +1 more source

Vaccine Preparedness for the Next Influenza Pandemic: A Regulatory Perspective

, 2022
The response to SARS-CoV-2 demonstrated the tremendous potential of investments in vaccine research and development to impact a global pandemic, resulting in the rapid development and deployment of lifesaving vaccines.
Goodman, Jesse L., Norman W. Baylor, Jesse L. Goodman, Baylor, Norman W.   +3 more
core   +1 more source

Research Progress of Universal Influenza Vaccine

Vaccines
Influenza viruses continue to undergo antigenic drift and shift, resulting in the need to update existing vaccines annually. Therefore, the development of a universal influenza vaccine has become an urgent global need. This paper reviews the functions of
Liangliang Wang, Qian Xie, Pengju Yu, Jie Zhang, Chenchen He, Weijin Huang, Youchun Wang, Chenyan Zhao   +7 more
doaj   +1 more source

Egg-Independent Influenza Vaccines and Vaccine Candidates

Vaccines, 2017
Vaccination remains the principal way to control seasonal infections and is the most effective method of reducing influenza-associated morbidity and mortality.
I. Manini, C. Trombetta, G. Lazzeri, T. Pozzi, S. Rossi, E. Montomoli   +5 more
semanticscholar   +1 more source

Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals [PDF]

, 2014
The human population is constantly exposed to multiple influenza A subtypes due to zoonotic spill over and rapid viral evolution driven by intrinsic error-prone replication and immunological pressure.
Ferrara, Francesca, Temperton, Nigel J., Temperton, Nigel, Lapini, Giulia, Molesti, Eleonora, Montomoli, Emanuele   +5 more
core   +1 more source

M2e-Based Universal Influenza A Vaccines

Vaccines, 2015
The successful isolation of a human influenza virus in 1933 was soon followed by the first attempts to develop an influenza vaccine. Nowadays, vaccination is still the most effective method to prevent human influenza disease.
Lei Deng, Ki Joon Cho, Walter Fiers, Xavier Saelens   +3 more
doaj   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source